

PUBLIKACJE 2017
Kliniki Chorób Zakaźnych i Hepatologii UMB
IF: 33,642; MNiSW: 403

1: Gruszewska E, Wrona A, Gudowska M, Panasiuk A, Cylwik B, Lipartowska-Klimuk K, Flisiak R, Chrostek L. The transferrin isoforms in chronic hepatitis. *Clin Biochem.* 2017 Dec;50(18):1131-1135. doi: 10.1016/j.clinbiochem.2017.06.013. Epub 2017 Jun 30. PubMed PMID: 28673788.

IF2017: 2,584

MNiSW: 30

2: Rogalska-Taranta M, Jaroszewicz J, Flisiak R. Normalizing serum hepcidin but not α -1-antitrypsin level during effective treatment of chronic hepatitis C. *Clin Exp Hepatol.* 2017 Dec;3(4):203-208. doi: 10.5114/ceh.2017.71573. Epub 2017 Nov 16. PubMed PMID: 29260001; PubMed Central PMCID: PMC5734587.

MNiSW: 7

3: Wedemeyer H, Craxí A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, Pangerl A, Zhang Z, Martinez M, Bao Y, Calleja JL. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. *J Viral Hepat.* 2017 Nov;24(11):936-943. doi: 10.1111/jvh.12722. Epub 2017 Jul 3. PubMed PMID: 28480525.

IF2017: 4,237

MNiSW: 35

4: Pogorzelska J, Łapińska M, Kalinowska A, Łapiński TW, Flisiak R. Helicobacter pylori infection among patients with liver cirrhosis. *Eur J Gastroenterol Hepatol.* 2017 Oct;29(10):1161-1165. doi: 10.1097/MEG.0000000000000928. PubMed PMID: 28700364; PubMed Central PMCID: PMC5590811.

IF2017 - 2,014

MNiSW – 20

5: Flisiak R, Łucejko M, Mazur W, Janczewska E, Berak H, Tomaszewicz K, Mozer-Lisewska I, Kozielowicz D, Gietka A, Sikorska K, Wawrzynowicz-Syczewska M, Nowak K, Zarębska-Michaluk D, Musialik J, Simon K, Garlicki A, Pleśniak R, Baka-Ćwierz B, Olszok I, Augustyniak K, Stolarz W, Białkowska J, Badurek A, Piekarska A. Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. *Adv Med Sci.* 2017 Sep;62(2):387-392. doi: 10.1016/j.advms.2017.04.004. Epub 2017 May 26. PubMed PMID: 28554119.

IF2017: 2,064

MNiSW: 15

6: Świdorska M, Jaroszewicz J, Stawicka A, Parfieniuk-Kowerda A, Chabowski A, Flisiak R. The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease. *Clin Exp Hepatol.* 2017 Sep;3(3):127-134. doi: 10.5114/ceh.2017.68466. Epub 2017 Jun 21. Review. PubMed PMID: 29062902; PubMed Central PMCID: PMC5649483.

MNiSW: 7

7: Parfieniuk-Kowerda A, Swiderska M, Szulzyk T, Jaroszewicz J, Lapinski TW, Flisiak R. Serum Concentrations of Th17-Associated Interleukins and Autoimmune Phenomena are Associated with the Degree of Liver Damage in Alcoholic Liver Disease. *J Gastrointest Liver Dis.* 2017 Sep;26(3):269-274. doi: 10.15403/jgld.2014.1121.263.pak. PubMed PMID: 28922439.

IF2017 - 1,964

MNiSW – 20

8: Jacobson IM, Washington MK, Buti M, Thompson A, Afdhal N, Flisiak R, Akarca US, Tchernev KG, Flaherty JF, Aguilar Schall R, Myers RP, Subramanian GM, McHutchison JG, Younossi Z, Marcellin P, Patel K. Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. *Clin Gastroenterol Hepatol.* 2017 Jul;15(7):1087-1094.e2. doi: 10.1016/j.cgh.2017.01.032. Epub 2017 Feb 12. PubMed PMID: 28215615.

IF: 7,683

MNiSW: 40

9: Halota W, Flisiak R, Juszczak J, Małkowski P, Pawłowska M, Simon K, Tomasiewicz K. Polish Group of Experts for HCV. Recommendations for the treatment of hepatitis C in 2017. *Clin Exp Hepatol.* 2017 Jun;3(2):47-55. doi: 10.5114/ceh.2017.67782. Epub 2017 May 18. Review. PubMed PMID: 28856290; PubMed Central PMCID: PMC5497480.

MNiSW: 7

10: Flisiak R, Halota W, Jaroszewicz J, Juszczak J, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tomasiewicz K, Wawrzynowicz-Syczewska M. Polish Group of Experts for HBV. Recommendations for the treatment of hepatitis B in 2017. *Clin Exp Hepatol.* 2017 Jun;3(2):35-46. doi: 10.5114/ceh.2017.67626. Epub 2017 May 10. Review. PubMed PMID: 28856289; PubMed Central PMCID: PMC5497479.

MNiSW: 7

11: Flisiak R, Flisiak-Jackiewicz M. Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. *Expert Rev Gastroenterol Hepatol.* 2017 Jun;11(6):559-567. doi: 10.1080/17474124.2017.1309284. Epub 2017 Mar 24. Review. PubMed PMID: 28317409.

IF2017: 2,963

MNiSW: 25

12: Tronina O, Durlak M, Wawrzynowicz-Syczewska M, Buivydiene A, Katzarov K, Kupcinskas L, Tolmane I, Karpińska E, Pisula A, Karwowska KM, Bolewska B, Jabłkowski M, Rostkowska K, Jakutiene J, Simonova M, Flisiak R. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir+/Dasabuvir±Ribavirin (OBV/PTV/r+/DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. *Ann Transplant.* 2017 Apr 7;22:199-207. PubMed PMID: 28386057.

IF2017: 1,054

MNiSW: 20

13: Flisiak R, Pogorzelska J, Flisiak-Jackiewicz M. Hepatitis C: efficacy and safety in real life. *Liver Int.* 2017 Jan;37 Suppl 1:26-32. doi: 10.1111/liv.13293. Review. PubMed PMID: 28052633.

IF2017: 4.5
MNiSW: 35

14: Świdarska M, Jaroszewicz J, Parfieniuk-Kowerda A, Rogalska-Płońska M, Stawicka A, Panasiuk A, Flisiak R. Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease. *Mediators Inflamm.* 2017;2017:3480234. doi: 10.1155/2017/3480234. Epub 2017 Jul 30. PubMed PMID: 28827897; PubMed Central PMCID: PMC5554581.

IF2017: 3,549
MNiSW: 30

15: Gudowska M, Gruszewska E, Panasiuk A, Cylwik B, Swiderska M, Flisiak R, Szmitkowski M, Chrostek L. High serum N-terminal propeptide of procollagen type III concentration is associated with liver diseases. *Przegl Gastroenterol.* 2017;12(3):203-207. doi: 10.5114/pg.2017.70474. Epub 2017 Sep 30. PubMed PMID: 29123582; PubMed Central PMCID: PMC5672709.

MNiSW: 14

16: Kozłowski P, Parfieniuk-Kowerda A, Tarasik A, Januszkiewicz M, Czauż-Andrzejuk A, Łapiński TW, Flisiak R. Occurrence and clinical characteristics of hepatocellular carcinoma in the north-eastern Poland. *Przegl Epidemiol.* 2017;71(3):405-415. PubMed PMID: 29186938.

MNiSW: 12

17: Janczarek MŁ, Grzeszczuk A. Guidelines for HIV testing in Poland. *Wiad Lek.* 2017;70(2 pt 2):395-398. Polish. PMID: 29059664

MNiSW: 11

18: Parczewski M, Siwak E, Leszczyszyn-Pynka M, Cielniak I, Burkacka E, Pulik P, Witor A, Muller K, Zasik E, Grzeszczuk A, Jankowska M, Lemańska M, Olczak A, Grąbczewska E, Szymczak A, Gąsiorowski J, Szetela B, Bociąga-Jasik M, Skwara P, Witak-Jędra M, Jabłonowska E, Wójcik-Cichy K, Kamerys J, Janczarek M, Krankowska D, Mikuła T, Kozieł K, Bielec D, Stempkowska J, Kocbach A, Błudzin W, Horban A. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics. *J Int AIDS Soc.* 2017 Jul 17;20(1):21847. doi: 10.7448/IAS.20.1.21847. PMID: 28715160

19: Rogalska-Płońska M, Rogalski P, Leszczyszyn-Pynka M, Stempkowska J, Kocbach P, Kowalczyk-Kot A, Janczarek M, Grzeszczuk A. Hypertension, dyslipidaemia, and cardiovascular risk in HIV-infected adults in Poland. *Kardiol Pol.* 2017;75(12):1324-1331. doi: 10.5603/KP.a2017.0148. Epub 2017 Jul 17. PMID: 28715065

IF2017: 1,227
MNiSW: 15

20: Parczewski M, Leszczyszyn-Pynka M, Witak-Jędra M, Szetela B, Gąsiorowski J, Knysz B, Bociąga-Jasik M, Skwara P, Grzeszczuk A, Jankowska M, Barańkiewicz G, Mozer-Lisewska I, Łojewski W, Kozieł K, Grąbczewska E, Jabłonowska E, Urbańska A. Expanding HIV-1 subtype B transmission networks among men who have sex with men in Poland. *PLoS One.* 2017 Feb 24;12(2):e0172473. doi: 10.1371/journal.pone.0172473. eCollection 2017.

IF2017: 2,766
MNiSW: 35

21: Pogorzelska J, Łapiński TW. Toxic hepatitis caused by the excretions of the *Phyllomedusa bicolor* frog - a case report. *Clin Exp Hepatol*. 2017; 3(1): 33-34.
MNiSW: 7

22: Pogorzelska J, Grzeszczuk A, Wandalowicz A, Flisiak R. Prevalence of syphilis among patients living with HIV treated in Białystok HIV/AIDS Center. *HIV & AIDS Review* 2017; 16, 4: 265-268.
MNiSW 11

Doniesienia zjazdowe:

1. R Flisiak, D Zarebska-Michaluk, M Łucejko, W Kryczka, A Piekarska, E A. Karpinska, M Wawrzynowicz-Syczewska, B G. Bolewska, I Mozer-Lisewska, T Mikula, A Wiercinska-Drapalo, K Rostkowska, K Simon, K Karwowska, W Halota. Two years follow-up after treatment with Ombitasvir/Paritaprevir/ritonavir ±Dasabuvir ±Ribavirin, an interim analysis of CE-long study following the AMBER - real world experience study. *Hepatology*. 2017;66(S1): 149–1185; DOI: 10.1002/hep.29501

2. M Łucejko, R Flisiak. The quality of life improvement after effective hepatitis C treatment with directly acting antivirals. *Clin Exp HEPATOL* 2017; 3, 2: 112-113

3. P Kostro, M Bartoszewicz, A Panasiuk, M Łucejko, R Flisiak. Level of alfa-fetoproteine (AFP) in patients with hepatitis C treated direct antiviral agents (DAA). *Clin Exp HEPATOL* 2017; 3, 2: 114

4. R Flisiak, M Łucejko, D Zarębska-Michaluk, A Piekarska. Two years follow-up after treatment with Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin, an interim analysis of CE-long study following the AMBER study. *Clin Exp HEPATOL* 2017; 3, 2: 67 (prezentacja ustna)